The Effect of Doxycycline 100mg and Doxycycline 20mg in Treatment of Mild and Moderate Acne

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2008 by Shahid Beheshti Medical University.
Recruitment status was  Recruiting
Information provided by:
Shahid Beheshti Medical University Identifier:
First received: October 16, 2006
Last updated: January 22, 2008
Last verified: January 2008
The purpose of this study is to compare the safety and efficacy of twice daily subantimicrobial dose doxycycline 20mg with daily doxycycline 100mg in treatment of mild and moderate Acne.

Condition Intervention Phase
Drug: Doxycycline
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: The Effect of Doxycycline 100mg and Doxycycline 20mg in Treatment of Mild and Moderate Acne

Resource links provided by NLM:

Further study details as provided by Shahid Beheshti Medical University:

Estimated Enrollment: 100
Study Start Date: October 2005
Estimated Study Completion Date: October 2006

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Acne

Exclusion Criteria:

  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00388778

Contact: Parviz Toossi, M.D. 98-21-22744392

Iran, Islamic Republic of
Skin Research Center, Shaheed Beheshti Medical University Recruiting
Tehran, Iran, Islamic Republic of, 19899
Contact: Parviz Toossi, M.D.    98-21-22744392   
Principal Investigator: Parviz Toossi, M.D.         
Sub-Investigator: Nahid Mohtasham, MD         
Sponsors and Collaborators
Shahid Beheshti Medical University
Principal Investigator: Parviz Toossi, M.D. Shahid Beheshti Medical University
  More Information

No publications provided Identifier: NCT00388778     History of Changes
Other Study ID Numbers: src-pts-964
Study First Received: October 16, 2006
Last Updated: January 22, 2008
Health Authority: Iran: Ethics Committee

Additional relevant MeSH terms:
Pathologic Processes
Anti-Bacterial Agents
Anti-Infective Agents
Antiparasitic Agents
Antiprotozoal Agents
Pharmacologic Actions
Therapeutic Uses processed this record on November 25, 2015